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Abstract
Background
The knowledge of hereditary predisposition has changed our understanding of Pulmonary
Arterial Hypertension. Genetic testing has been widely extended and the application of Pul-
monary Arterial Hypertension specific gene panels has allowed its inclusion in the diagnostic
workup and increase the diagnostic ratio compared to the traditional sequencing tech-
niques. This is particularly important in the differential diagnosis between Pulmonary Arterial
Hypertension and Pulmonary Venoocclusive Disease.
Methods
Since November 2011, genetic testing is offered to all patients with idiopathic, hereditable
and associated forms of Pulmonary Arterial Hypertension or Pulmonary Venoocclusive Dis-
ease included in the Spanish Registry of Pulmonary Arterial Hypertension. Herein, we pres-
ent the clinical phenotype and prognosis of all Pulmonary Arterial Hypertension patients
with disease-associated variants in TBX4.
Results
Out of 579 adults and 45 children, we found in eight patients from seven families, disease-
causing associated variants in TBX4. All adult patients had a moderate-severe reduction in
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diffusion capacity. However, we observed a wide spectrum of clinical presentations, includ-
ing Pulmonary Venoocclusive Disease suspicion, interstitial lung disease, pulmonary vascu-
lar abnormalities and congenital heart disease.
Conclusions
Genetic testing is now essential for a correct diagnosis work-up in Pulmonary Arterial Hyper-
tension. TBX4-associated Pulmonary Arterial Hypertension has marked clinical heterogene-
ity. In this regard, a genetic study is extremely useful to obtain an accurate diagnosis and
provide appropriate management.
1. Introduction
Pulmonary Arterial Hypertension (PAH) is a severe and uncommon disease affecting small
pulmonary arteries with an increase in pulmonary vascular resistance, which leads to right
ventricle failure and death [1]. In the last two decades, knowledge of hereditary predisposition
to PAH has drastically increased. In 2000, mutations in the Bone Morphogenic Protein Recep-
tor Type 2 (BMPR2) gene were identified in families with heritable PAH [2, 3]. Since then, the
importance of genetic testing and counselling has been steadily increasing. Genetic testing has
been included in the diagnostic workup in the European Respiratory Society (ERS) and the
European Society of Cardiology guidelines (ESC) [4].
The initial molecular approach to PAH testing was the use of Sanger sequencing. However,
this is no longer appropriate due to a large number of genes currently known to be associated
with the condition. To date, 12 genes have been associated with PAH with a high level of evi-
dence and 5 with a low level of evidence [5]. Furthermore, the hypothesis of a digenic pattern
of inheritance makes necessary novel approaches using Next Generation Sequencing (NGS) to
obtain information from a set of genes, the entire exome or even the whole genome [6].
One of these recently associated genes encodes the T-box transcription factor 4 (TBX4),
which is involved in the regulation of embryonic developmental processes. Pathogenic variants
in TBX4 are a well-established cause of PAH in children, typically associated with skeletal dis-
orders (small patella syndrome, MIM #147891), intellectual disabilities and other cardiovascu-
lar disorders [7–11]. Mutations in this gene might also lead to diffuse developmental disorders
in the lungs in neonates [12, 13].
Pulmonary Venooclusive Disease (PVOD) is the most lethal subtype of PAH, with different
clinical, histological and genetic features [14–16]. Definitive diagnosis can be established by
either histological analysis or by the presence of biallelic pathogenic variants in the Eukaryotic
Translation Initiation Factor 2 Alpha Kinase 4 (EIF2AK4) gene [4]. Clinical diagnosis includes
the combination of very low diffusion capacity (DLCO), resting hypoxemia, severe desatura-
tion on exercise and a characteristic radiological pattern (ground-glass opacification, interlob-
ular septal thickening and mediastinal lymphadenopathy) [14]. However, the differential
diagnosis between PAH and PVOD represents a clinical challenge and misdiagnosis is a com-
mon problem [17, 18]. The importance of an accurate diagnosis lies in the specific manage-
ment that must be provided to PVOD patients: close follow-up and early referral to lung
transplantation units [4]. When PVOD is suspected, pulmonary vasodilators should be pre-
scribed with caution due to the risk of pulmonary oedema and respiratory insufficiency wors-
ening [14, 15].
PH associated with Congenital Heart Disease (CHD) is a PAH subtype and represents a
heterogeneous group of patients. Patients with CHD have an increased pulmonary blood flow
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that can lead to unfavourable vascular remodelling and PH. It is estimated that 5–10% of
patients with CHD develop PH [19]. However, the role of genetic mutations in the develop-
ment of pulmonary vascular disease remains unclear.
This study aimed to describe the phenotype of PAH associated with TBX4 variants. Herein,
we present data from Spain’s nationwide PAH registry to identify clinical, radiological and his-
tological patterns of TBX4 variants.
2. Methods
Study patients
Patients with idiopathic, hereditable and associated forms of PAH, and PVOD included the
Spanish Registry of Pulmonary Arterial Hypertension (REHAP) and the Registry of Pediatric
Pulmonary Hypertension Patients (REHIPED) were eligible for this study. REHAP and
REHIPED are observational national registries with researching purposes that include patients
with Group 1 and Group 4 Pulmonary Hypertension. A full list of REHAP and REHIPED cen-
ters and investigators is provided in the Supporting Information.
Pulmonary Arterial Hypertension was defined according to the 2015 ERS/ESC Guidelines
for the Diagnosis and Treatment of Pulmonary Hypertension [4]. Right Heart Catheterism
(RHC) at diagnosis includes Right Atrium Pressure, Mean Pulmonary Artery Pressure, Pul-
monary Wedge Pressure, Cardiac Output, Cardiac Index and Pulmonary Vascular Resistance.
Pulmonary vasoreactivity testing was performed in Idiopathic PAH (IPAH), Hereditable PAH
(HPAH) and drug-induced PAH. Routine diagnostic workup included medical history, physi-
cal examination, 6-minute Walking Test (6MWT), echocardiogram, Multidetector Computed
Tomography (MDCT), ventilation/perfusion lung scan, pulmonary function tests (PFT), and
screening of Connective Tissue Disease, HIV infection and Portal Hypertension. PFT included
the diffusing capacity for carbon monoxide (DLCO), which was considered moderately
reduced when DLCO 43–62% of predicted values and severely reduced when DLCO < 43% of
predicted values [20]. For this study, a comprehensive assessment was conducted to identify
other conditions typically associated with TBX4 variants: skeletal disorders, congenital heart
disease, intellectual impairment, or neurological disorders. Therapeutic management is left to
the discretion of individual physicians.
Since November 2011, genetic studies have been offered to all patients included in REHAP
and REHIPED registries with idiopathic, hereditable and associated forms of PAH, and
PVOD. The ethical principles of the European Board of Medical Genetics and the 2015 ERS/
ESC Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension are to offer
accurate information on the range of options available to make informed decisions and to
allow equal access to genetic counselling and testing [4]. Pre and post-test genetic counselling
were provided. All patients or legal tutors included in the analysis gave their written informed
consent and the project was approved by the ethical committee for scientific research of the
participant centers. We obtained written parental consent from parents or guardians of minors
included in this study. A full list of REHAP and REHIPED centers and investigators is pro-
vided in the Supporting Information. In the pre-test visit, family history information was col-
lected, but only probands were studied. When a positive result was observed, a genetic study
was offered to first degree relatives when available. Cascade or cosegregation genetic tests were
also performed. When an unaffected carrier was identified, a complete diagnostic was per-
formed, including electrocardiogram, echocardiogram, N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) and 6 Minute Walking Test. Due to the typical phenotype, DLCO was also
determined in healthy carriers. This evaluation is periodically repeated. When a sustained sus-
picion of early-stage PAH was observed, RHC was performed to rule out the condition.
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Molecular analysis
A PAH-specific 21 genes NGS panel was designed (HAP v1.2). Genes included are divided
into: TGF-β signalling pathway-related genes (BMPR2, BMPR1B, GDF2, SMAD1, SMAD4,
SMAD5, SMAD9, ENG, ACVRL1 and CAV1); recently described genes in PAH (KCNK3,
KCNA5, NOTCH3, TBX4, TOPBP1, MMACHC9); genes associated with PVOD (EIF2AK4)
and candidate genes (SARS2, CPS1, ABCC8, CBLN2).
HAP v1.2 was designed with NimbleDesign (Roche, EEUU). Fragmentation and capture of
the target regions were performed with SeqCap EZ Choice Enrichment Kit (Roche, EEUU)
and sequencing was carried out in the IlluminaMiSeq platform (Illumina, EEUU). The in-
house bioinformatics pipeline was developed to analyze the raw data. After the filtering of the
relevant variants, validation of the candidate variants was carried out through traditional
Sanger Sequencing. Review, classification and interpretation of the variants were made accord-
ing to the American College of Medical Genetics and Genomics (ACMG) guidelines [21].
Copy Number Variations (CNV) analysis was performed by applying a custom script
named “LACONv” (https://github.com/kibanez/LACONv), which has been developed in-
house. It detects gains and losses in the genes included in the HAP v1.2 panel. Minimal depth
by sample to be considered: 20X; Minimal depth in genomic intervals to be considered: 15X;
Doses rate threshold for deletions: 0.60; Doses rate threshold for duplications: 1.20; Zscore
threshold to establish CNVs (deletions): -2.000. Single Nucleotide Polymorphism (SNP)
microarray validation of detected deletion through NGS was performed (Infinium OmniEx-
pressExome-8 v1.6 Kit Illumina).
Pathogenicity prediction has been calculated by nine tools included in the dbNSFP algo-
rithm plus CADD. Values to classify according to each predictor is detailed in Liu et al., 2015,
Hum Mut (hay que meter la referencia, PMID: 26555599). For CADD, we established a thresh-
old of 14 of the Phred score, being those values above it classified as damaging and the rest as
neutral.
Radiological assessment
Multidetector Computed Tomography (MDCT) images, when available, were reviewed by a
cardiothoracic radiologist expert in PH imaging. Images were assessed for the presence of
ground-glass opacification, interlobular septal lines, lymph node enlargement, pleural effusion,
pericardial effusion and other remarkable findings. When two or more radiological abnormal-
ities typical of PVOD (grounds grass opacification, interlobular septal thickening or mediasti-
nal lymphadenopathy) were present, the radiological diagnosis was possible PVOD [22].
Histological analysis
Histopathological evaluation was performed using hematoxylin-eosin-stained 5 μm slides
from formalin-fixed paraffin-embedded lung obtained during a biopsy or after lung transplan-
tation. Representative sections from each lobe of both lungs were obtained after lung trans-
plantation. Specimens included vascular and bronchial surgical margin, hilar lymph nodes,
and five or more representative samples of each lobe. Any remarkable macroscopic finding
was included. Pulmonary arteries were evaluated for PAH signs such as medial hypertrophy/
hyperplasia, intimal and adventitial fibrosis, and thrombotic lesions, plexiform lesions [23].
PVOD involvement was defined as an extensive and diffuse obstruction of pulmonary veins
and venules by intimal thickening, with either fibrosis, cellular proliferation, or musculariza-
tion [14, 23]. Samples were also evaluated for the presence of parenchymal lung disease, diffuse
developmental disorders, and growth abnormalities [24].
PLOS ONE A novel phenotype in TBX4 carriers
PLOS ONE | https://doi.org/10.1371/journal.pone.0232216 April 29, 2020 4 / 23
3. Results
579 adults and 45 children have been included in this study. Baseline characteristics of the
adult and the pediatric cohorts are shown in Tables 1 and 2. Six different heterozygous variants
were identified in the 8 subjects and consisted of 2 Copy Number Variants involving the
17q23.2 locus and 4 TBX4 Single Nucleotide Variants. Two of these mutations had been previ-
ously reported by our group and by Galambos et al., respectively [8, 15]. See Table 3 for a sum-
mary of patients and Table 4 for variants analysis. Furthermore, two Variants of Unknown
Significance were identified in two adult patients with children-onset PAH. Clinical pheno-
types, available histological analysis (patients 1 and 3) and variants analysis of each family are
provided below.
Family 1
Patient 1 and patient 2 (patient 1 mother) presented a pathogenic variant in TBX4
(NM_018488.3:c.308_310dupAAG;p.Lys103_Val104insGlu) previously published by our
group (Fig 1) [25]. Segregation analysis revealed that three other family members also carry
the variant (patient 1 uncle, patient 1 sister, patient 1 niece). PAH was initially ruled out in rel-
atives and carriers are periodically evaluated.
These two patients were diagnosed at 26 and 59 years of age, respectively. Patient 1 was ini-
tially diagnosed with Interstitial Lung Disease. In the MDCT, she had interlobular septal thick-
ening and emphysema radiological pattern with peripheral distribution (Fig 2). In the initial
diagnostic workup, she underwent a lung biopsy, which confirmed Non-specific Interstitial
Pneumonia, with fibrotic pattern and the presence of peribronchial and perivascular granulo-
mas (Figs 3–6). Pulmonary Function Test showed a mild restrictive pattern (Total Lung
Capacity (TLC) 74% of predicted) and severe diffusion capacity reduction (Diffusing Capacity
Table 1. Baseline characteristics of adult cohort.
Age, years 45 (± 0,76)




Pulmonary Venooclusive Disease 54 (9.33%)
Connective Tissue Disease 91 (15.72%)
Congenital Heart Disease 88 (15.2%)
Drugs 22 (3.8%)
Portopulmonary Hypertension 11 (1.9%)
Hereditary Hemorrhagic Telangiectasia 7 (1.21%)






North African 6 (1%)
Asian 1 (0.2%)
Hindu 1 (0.2%)
Data are median (range), mean (SD), or n (%).
https://doi.org/10.1371/journal.pone.0232216.t001
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Table 2. Baseline characteristics of paediatric cohort.
Age, years 9.9 (± 4.4)




Pulmonary Venooclusive Disease 3 (6.7%)






Data are median (range), mean (SD), or n (%).
https://doi.org/10.1371/journal.pone.0232216.t002
Table 3. Clinical characteristics.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
PAH-onset Adult Adult Adult Adult Adult Child Child Child
Initial Diagnosis Familial Familial Idiopathic Idiopathic Idiopathic CHD Idiopathic Idiopathic
Gender Female Female Female Male Male Male Female Female
Follow-up, years 11 4 9 2.1 5 16 8 1.5
Final status Alive Alive Transplant Death Alive Alive Alive Alive
Radiological Diagnosis ILD PAH PVOD PVOD PAH PAH PAH ILD
Skeletal Disorder Absent Absent Absent Absent Absent Arthritis Growth delay Absent
CHD Absent Absent Absent Absent Absent OS ASD Absent PDA, PFO
Neurologic/
psychomotor deficits
Absent Absent Absent Absent Absent Absent Developmental delay
Nystagmus
Hearing loss
DLCO, % predicted 34 29 55 32 61 49 NA NA
VFC, % predicted 56 98 86 115 58 70 NA NA
FEV1, % predicted 53 82 66 104 140 70 NA NA
mPAP, mmHg 50 49 75 38 49 61 36 39
PCWP, mmHg 8 7 24 9 7 10 12 11
CO, l/min 3.8 2.8 3.5 3.45 6.3 3.1 2.9 1.6
CI, l/min/m2 2.3 1.99 2.02 1.95 3.4 1.5 4.9 4.7
PVR, WU 11 15 15 8.4 6.7 16.5 4.9� 6�
AVT Negative Negative Negative Negative Positive NA Positive Positive












ERA + PDE5i + CCB PDE5i + syst
PC
DLCO: Diffusing Capacity of the Lung for Carbon Monoxide; VFC: Vital Forced Capacity; FE1V: Forced Expiratory Volume in 1 second; mPAP: mean Pulmonary
Artery Pressure; PCWP: Pulmonary Capillary Wedge Pressure; CO: Cardiac Output; CI: Cardiac Index; PVR: Pulmonary Vascular Resistance; WU: Wood Units; AVT:
Acute Vasoreactivity Testing; ERA: Endothelin Receptor Antagonist; PDE-5i: Phosphodiesterase Type 5 Inhibito; CCB: Calcium Channel Blocker; PAH: Pulmonary
Artery Hypertension; PVOD: Pulmonary Venooclusive Disease; CHD: Congenital Heart Disease; Syst PC: systemic prostacyclin; PDA: Patent Ductus Arteriosus; PFO:
Patent Foramen Ovale; ILD: Interstitial Lung Disease
� Indexed PVR, UW.m2
https://doi.org/10.1371/journal.pone.0232216.t003
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1 chr17:59543206dupAAG c.308_310dupAAG: p.
(Lys103_Val104insGlu)
3 duplication 0 1/1 P maternal Navas et al
[25]
2 chr17:59544901G>T c.432G>T:p.(Met144Ile) 4 missense 4.06e-06 8/10 LP maternal This study
3 chr17:59544901G>T c.432G>T:p. (Met144Ile) 4 missense 4.06e-06 8/10 LP PD This study
4 chr17:59557681G>A c.1021+1G>A 7 splicing 0 4/4 P N/D This study
5 chr17:59544901G>T c.1019C>T:p. (Arg340�) 8 nonsense 0 8/10 P N/D Galambos
et al. [8]
6 TBX4 deletion N/A N/A N/A N/A N/A LP De novo Kerstjens-
Frederikse
et al [7]
7 TBX4 deletion N/A N/A N/A N/A N/A LP De novo Kerstjens-
Frederikse
et al [7]
† gnomAD exomes, gnomAD genomes, Kaviar, 1000G phase III, ESP
‡ dbNSFP (MutationTaster, MutationAssessor, FATHMM, FATHMM-MKL, MetaSVM, MetalR, Provean, LRT, SIFT)
§ ACMG prediction: P:Pathogenic, LP: Likely Pathogenic
¶ N/R: Not done; PD: parents death
https://doi.org/10.1371/journal.pone.0232216.t004
Fig 1. Family 1 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g001
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Fig 2. Patient 1 Multidetector Computed Tomography. Subtle emphysema radiological pattern with peripheral
distribution (red arrows).
https://doi.org/10.1371/journal.pone.0232216.g002
Fig 3. Patient 1 lung biopsy. Pulmonary artery without significative lesions (arrow).
https://doi.org/10.1371/journal.pone.0232216.g003
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Fig 5. Patient 1 lung biopsy. Masson Trichrome staining showing an emphysematous change with muscle cell
hyperplasia (arrow).
https://doi.org/10.1371/journal.pone.0232216.g005
Fig 4. Patient 1 lung biopsy. Peripheral area. A septum is shown (arrow) with a vein without significant changes. Note
the granuloma and giant cells with prominent intracytoplasmic cholesterol clefts (arrowhead).
https://doi.org/10.1371/journal.pone.0232216.g004
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of the Lung for Carbon Monoxide (DLCO) 37% and Coefficient for Carbon Monoxide (KCO)
67% of predicted, respectively). Immunosuppressive therapy was prescribed with azathioprine.
During follow-up, goal-oriented PAH therapy was applied and risk profile assessed periodi-
cally. Currently, she receives systemic prostanoids and has been referred to the lung transplant
unit for evaluation.
Patient 2 does not have radiological signs suggestive of interstitial lung disease. The only
remarkable finding was a subtle emphysema pattern. She is also in treatment with systemic
prostanoids.
Family 2
Patient three presented a missense variant (NM_018488.3:c.432G>T; p.(Met144Ile). This vari-
ant has not been previously published in the literature and showed an extremely low frequency
in the control population (gnomADexomes: 4,06x10-6, gnomAD genomes: 0, Kaviar: 0,
EVS:0). On gnomADexomes v2.0.2 there is only one carrier in the Latino population (1/
246213). The phenotype of this subject is unknown. The majority of the bioinformatic patho-
genicity prediction tools suggested a pathogenic effect (8/10). The prevalence of this variant in
affected individuals is significantly increased when compared with controls. Following ACMG
guidelines, we consider this variant likely pathogenic [21]. The family screening revealed that
her mother also carried the variant. After a comprehensive study, PAH was ruled out. Genetic
Counseling was provided to the rest of the family (Fig 7).
Fig 6. Patient 1 lung biopsy. Masson Trichrome staining showing pulmonary fibrosis (arrow) near the airway. Note
also muscle cell hyperplasia (arrowhead).
https://doi.org/10.1371/journal.pone.0232216.g006
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Patient 3 is a Caucasian female diagnosed with PAH at 28 years of age. She was clinically
diagnosed with possible PVOD due to radiological findings and reduced diffusion capacity. At
diagnosis, oral therapy with Phosphodiesterase 5 inhibitors (PDE5i) and Endothelin Receptor
Antagonist (ERA) was prescribed. Initially, the patient responded favourably to vasodilator
treatment. Six years after diagnosis, she progressively worsened and treatment had to be esca-
lated. Systemic prostanoids had to be added and treprostinil was titrated up to optimal dose.
She did not develop pulmonary oedema after treatment with prostanoids. Despite optimal
medical treatment, she presented a high risk of death and was listed for lung transplantation.
Nine years after diagnosis, she underwent bilateral lung transplantation. MDCT study at diag-
nosis showed subtle ground grass and septal thickening (Fig 8). Histological analyses after
transplantation reveal typical PAH findings (Fig 9). PVOD and Interstitial Lung Disease were
also ruled out in explanted lung tissue (Fig 9).
Family 3
Patient 4 also presented the same missense variant (NM_018488.3: c.432G>T; p.(Met144Ile))
documented in patient 3 (See Above). Patients 3 and 4 are not related and came from different
regions of the country. Patient 4 parents’ had died before PAH diagnosis and before genetic
tests could be offered. Genetic counselling has been provided to the rest of the family. The rest
of the family members rejected genetic testing (Fig 10).
Patient 4 was a Caucasian male diagnosed with PVOD at 62 years of age. Initially, he dis-
played poor clinical status, showing heart failure signs and severe respiratory insufficiency.
The radiological study was highly suggestive of PVOD with the typical triad (Fig 5) [14].
Referred to the lung transplant unit, he was not eligible due to advanced age and comorbidi-
ties. The clinical course was rapidly progressive and he died 26 months after diagnosis.
Fig 7. Family 2 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g007
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Fig 8. Multidetector Computed Tomography patients 3 and 4. (A) Patient 3 interlobular septal thickening (red
arrow) (B) Patient 3 ground grass pattern (yellow arrow) (C) Patient 4 mediastinal lymphadenopathies (green arrow)
(D) Patient 4 interlobular septal thickening (red arrows).
https://doi.org/10.1371/journal.pone.0232216.g008
Fig 9. Patient 3 explanted lung tissue. Typical PAH findings, without venous or venular lesions. (A) Vascular
structure with glomeruloid morphology. 10X view H&E stain. (B) Artery intimal thickening (arrow). 4X view H&E
stain. (C) Lung parenchyma with emphysema signs with dilated alveolar spaces and incomplete alveolar septa (star),
increase in vascularization and capillary dilation (blue arrow) and artery medial hypertrophy (green arrow). 4X view
H&E stain. (D) Artery intimal thickening (arrow). 10X view H&E stain. (E) Artery medial hypertrophy (green arrow)
(F) Dilated alveolar spaces (star). 4X view H&E stain.
https://doi.org/10.1371/journal.pone.0232216.g009
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Family 4
Patient 5 showed a splicing variant (c.1021+1 G>A), not previously published. The majority
of the pathogenic bioinformatics tools predicted a pathogenic effect for the variant. The splic-
ing prediction software also showed a possible effect on splicing with a new possible cryptic
splice site at +30bp. This variant has not been found in the analyzed control population data-
bases (Table 2). Functional analysis of this variant by minigenes assay confirmed the alterna-
tive splicing with exon 6 and 7 skippings (data in publishing). The variant was classified as
pathogenic following ACMG guidelines [21]. No other variants were observed in the rest of
the genes included in the panel, including genes related to Hereditary Hemorrhagic Telangiec-
tasia (ENG, ACVLR1). The patient had a son who died in the perinatal period due to severe
PH and multiple vascular malformations. Cascade screening was rejected by the other family
members (Fig 11).
Patient 5 was diagnosed with PAH at 31 years of age. Hereditary Hemorrhagic Telangiecta-
sia (HHT, Osler-Weber-Rendu syndrome) was initially suspected. In the CT scan at diagnosis,
he had marked collateral circulation with hypertrophy in mammary, phrenic and bronchial
arteries (Fig 12). In the RHC, a high cardiac output was observed. A comprehensive study was
performed to find arteriovenous malformations in other sites and they were not observed. Due
to the lack of other clinical findings, HHT was not confirmed. In the initial RHC, he had a pos-
itive acute response in the vasoreactivity test. However, we observed unresponsiveness to long-
term Calcium Channel Blockers (CCB) and PAH-targeted treatment had to be added.
Family 5
Patient 6 showed a nonsense mutation in TBX4 (TBX4:NM_018488.3:c.1018C>T:p.
(Arg340�)). The variant has previously been reported by Galambos et al. and classified as
Likely Pathogenic [8]. He also carries a variant in exon 4 of gene SMAD1 (c.738G>C(p.
Met246Ile)). This sequence change replaces methionine with isoleucine at amino acid 246.
The variant has been found at extremely low frequency or is absent in the analyzed control
population databases (gnomAD exomes, gnomAD genomes, Kaviar, ESP, 1000G, Beacon).
Fig 10. Family 3 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g010
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Most pathogenic bioinformatics tools suggested that this variant impaired the function of the
encoded protein. Following ACMG guidelines, this variant was considered of unknown signif-
icance [21]. Genetic counselling has been provided to the rest of the family. However, cascade
screening was rejected (Fig 13).
Patient 6 was first diagnosed with PH in childhood and referred to our center at 24 years of
age. Secundum Atrial Septal Defect (ASD) was observed in the initial diagnostic workup. The
larger diameter was 2 cm and right-to-left shunting was present. Severe PAH was confirmed
in the RHC. Considering these findings, ASD closure was contraindicated. It is also remark-
able a moderate reduction in diffusion capacity (58% of predicted) and severe respiratory
insufficiency. Ambulatory oxygen therapy was initiated after diagnosis. Due to the clinical
Fig 11. Family 4 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g011
Fig 12. Multidetector Computed Tomography patient 5. Hypertrophy in mammary (green arrows), phrenic (red
arrows) and bronchial arteries (blue arrows).
https://doi.org/10.1371/journal.pone.0232216.g012
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situation, combination therapy was initiated and a goal-oriented strategy was applied. Two
years after diagnosis, inhaled iloprost was initiated and currently, he receives systemic
prostanoids.
Family 6
We identified a 2.2 MB CNV deletion involving TBX4 in patient 7, which encompasses 17
genes and potential genes (CA4, LOC645638, HEATR6, LOC653653, SCARNA20, USP32,
C17orf64, APPBP2, PPM1D, TBX2, BCAS3, C17orf82, TBX4, NACA2, BRIP1, INTS2 and
MED13) (Fig 14). She was diagnosed with Persistent Pulmonary Hypertension of the Newborn
(PPHN) at the age of 4 months. Her mother had previously had two spontaneous abortions.
The histological analysis of one of them showed pulmonary hypoplasia. Both parents are
healthy. PAH and lung disease were ruled out in her brother (Fig 15).
In imaging studies, there was no evidence of parenchymal lung disease. She had bilateral
nystagmus, which required surgery. She also showed mild growth and neurodevelopmental
delay. At diagnosis, dual oral therapy was initiated with ERA and iPDE5 until she was five
Fig 13. Family 5 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g013
Fig 14. SNP microarray validation of detected deletion through NGS in patients 7 and 8.
https://doi.org/10.1371/journal.pone.0232216.g014
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years old. RHC was repeated and we observed a positive response to the vasoreactivity test. A
Calcium Channel Blocker was added and long-term response to CCB was confirmed with near
normalization hemodynamic parameters (Indexed PVR 3.1 UW.m2 and mPAP 18 mmHg).
Family 7
The same 2.2Mb CNV observed in patient 7 was detected in patient 8. She was diagnosed with
suprasystemic PAH 8 days after birth. Both parents and her 3-year-old brother have no signs
of PAH or lung disease (Fig 16).
She was initially treated with sildenafil and the hemodynamic situation was reassessed at 4
months of age. In the RHC, severe precapillary PH was confirmed and we observed partial
positive response to acute vasodilator test. Treprostinil was initiated and titrated up to medium
dose. She responded favourably to PAH-targeted treatment with clinical improvement and
proper growth. Imaging studies showed Patent Ductus Arteriosus and Patent Foramen Ovale.
Fig 15. Family 6 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g015
Fig 16. Family 7 pedigree.
https://doi.org/10.1371/journal.pone.0232216.g016
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She also had radiological signs of Interstitial Lung Disease and initially needed oxygen
(Fig 17).
4. Discussion
In this study, we describe our experience with PAH possibly associated with TBX4 variants.
The most important finding is a moderate to a severe reduction in diffusion capacity in all
adult-onset patients. Apart from this, we observe a wide spectrum of clinical phenotypes,
which have not been previously described.
A diffusion capacity reduction in TBX4-associated PAH is a novel finding. A recent study
by Gräf et al. studied a large PAH cohort, which included 1048 patients [26]. Fourteen of them
carried a pathogenic variant in the TBX4 gene, with a mean age of 56.5 years (39.9–71.8 years).
In this group of patients, diffusion capacity was not reduced and the mean KCO was 89.7%
(83.3-91-8%).
TBX4 variants are a common cause of hereditable PAH in infants and children. Pediatric
PAH due to TBX4 mutations is typically associated with musculoskeletal disorders, congenital
heart disease and intellectual disability [7–11]. Kerstjens-Frederikse et al. first described TBX4
mutations or deletion in 6 children with PAH and Small Patella Syndrome [7]. A recent study
assessed clinical and histological data in 19 children carrying TBX4 variants [8]. These patients
had Persistent Pulmonary Hypertension in Neonates (PPHN), childhood-onset PH and lung
development abnormalities. A distinctive biphasic pattern was observed in 12 /19 infants. This
pattern consists of PPHN or transient respiratory distress with improvement or resolution, fol-
lowed by PH diagnosed in the pediatric period (median age 1.5 years).
However, a typical phenotype has not been described in an adult population. In our study,
a common finding in adult-onset patients with PAH carrying possibly associated pathogenic
Fig 17. Patient 8 chest X-ray at 4 months.
https://doi.org/10.1371/journal.pone.0232216.g017
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variants in TBX4 is a moderate to severe DLCO reduction. This is a typical finding in PAH
associated with scleroderma, PVOD or PH from group 3 [14, 27, 28]. In PH from Group 1, a
decreased DLCO is associated with advanced age, male, reduced peak oxygen uptake and
higher Functional Class. Furthermore, previous studies suggest DLCO as a prognostic marker
in PAH [29, 30].
In our study, we observed eight patients with PAH possibly associated with TBX4 variants
and four healthy carriers. This incomplete penetrance is a hallmark of hereditable PAH. The
presence of a pathogenic variant is required but insufficient alone for clinical expression. Fur-
thermore, this study highlights variable expression both within and between families. Patients
1–2 and patients 3–4 carry the same variant, respectively. However, age at diagnosis, clinical
phenotype and prognosis are completely different in each patient. Additional genetic or envi-
ronmental factors may affect the clinical expression. The different clinical phenotypes
observed in our population are described below.
Despite an ever-growing knowledge of PAH, the differential diagnosis between PAH and
PVOD remains a clinical challenge [18, 31]. Hadinnaopla et al. have recently demonstrated
that genetic testing is a useful tool in the differential diagnosis in patients with overlapping
clinical features [17]. In this study, up to 36% PVOD patients were initially diagnosed with
PAH and reclassified after genetic testing.
In our study, PVOD was suspected in two patients based on imaging, severe respiratory
insufficiency and diffusion reduction. Patient 3 was treated with PAH targeted therapy, includ-
ing high doses of systemic prostanoids. Despite the suspicion she responded favourably, with
clinical and functional stabilization, making the PVOD diagnosis unlikely. Genetic testing sub-
sequently ruled out EIF2AK4 mutations and histological analysis showed no signs of PVOD.
On the other hand, patient 4 had an aggressive form and a rapidly progressing course. Given
the initial suspicion of PVOD, PAH targeted therapy was prescribed with caution and no sys-
temic prostanoids were administered. This conservative management, clearly determined ini-
tial suspicion of PVOD, might have influenced the progressive clinical course observed.
These findings reflect the complexity of phenotyping PH. PVOD-like involvement is a
major issue in PAH. Although a high probability diagnosis of PVOD can be achieved by the
combination of clinical features, pulmonary function test and radiological findings, a definitive
diagnosis can only be established by histological or genetic analysis. Clinical genetic testing is
of value in the early identification of PVOD. However, as previously reported by our group,
the prognosis is mainly determined by the tolerance to pulmonary vasodilator independently
of the presence or absence of an underlying biallelic EIF2AK4 mutation [15]. Furthermore, a
favourable clinical response to PAH therapy runs against classic PVOD.
TBX4 pathogenic variants can also lead to lung lethal lung developmental disorders. Karo-
lak et al. have recently published a large series of 26 neonate deceased patients with acinar dys-
plasia, congenital alveolar dysplasia and other rare lung hypoplasia due to disruption of the
TBX-FGF pathway [13]. They identified rare heterozygous copy-number variant deletions or
single-nucleotide variants involving TBX4 in 8 and 2 patients, respectively. Furthermore, dif-
ferent genes have been associated with Idiopathic Interstitial Pneumonia. The majority of the
pathogenic variants were identified in the surfactant genes SFTPA1, SFTPA2, SFTPB, SFTPC,
ABCA3, and NKX2-1 [32].
In our series, patient 1 was diagnosed with Non-Specific Interstitial Pneumonia. She under-
went lung biopsy due to clinical and radiological findings. In the histological analysis, intersti-
tial fibrosis without temporal heterogeneity and cholesterol granulomas were present.
Pulmonary Function Testing was mildly impaired and radiological parenchyma abnormalities
were only modest. These, together with the TBX4 pathogenic variant, are criteria favouring
Group 1 PH. Contextualizing PH severity, pulmonary hypertension cannot be easily explained
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by the presence of a mild form of lung disease. The most plausible interpretation is that the
patient suffers from hereditable PAH associated with a TBX4 variant and probable paren-
chyma lung disease. These findings are in line with a case recently published by Maurac et al.
[33]. They report a patient with parenchymal pulmonary abnormalities, airway diverticula,
small patella syndrome, and PAH. Despite the lung pathology, PAH was the most plausible
diagnosis. Furthermore, Eyries et al. have recently shown a similar phenotype in PAH associ-
ated with KDR mutations [34]. They describe two PAH patients with mild Interstitial Lung
Disease and low DLCO who carried a loss-of-function mutation in the KDR gene. In one fam-
ily, segregation analysis revealed that the variant was associated with reduced DLCO, with or
without PAH. Further investigations are needed to address the relation between TBX4 or
other PAH genes and interstitial lung diseases.
Patient 5 had anomaly enlarged systemic arteries and high cardiac output at diagnosis.
Hereditary Hemorrhagic Telangiectasia was initially suspected. However, typical Pulmonary
Arteriovenous Malformations were not present and HHT was not confirmed. Furthermore,
no variants were observed in genes associated with HHT (ENG and ACVRL1). His son died on
the first day of life due to a severe form of pulmonary vascular malformation and pulmonary
hypertension. The infant probably had a different clinical manifestation associated with TBX4
variants.
Patients with HAP often show Bronchial Arteries (BA) enlargement, which might reflect
the role of preexisting Intrapulmonary Bronchopulmonary Anastomoses (IBA) [35, 36]. An
increase in Pulmonary Artery resistance might lead to an increased flow toward an open IBA
and, subsequently, Bronchial Arteries. Furthermore, this phenomenon might contribute to the
development of vascular plexiform lesions. Calambos et al. have provided histologic evidence
supporting these findings in patients with IPAH and patients with PH associated with TBX4
variants. This mechanism might underlie the vascular abnormalities observed in patient 5.
Patient 6 has PAH associated with a non-repaired Atrial Septal Defect. Previous studies
have observed that mutations in BMPR2 are present in up to 7.5% of patients with PAH associ-
ated with CHD [37, 38]. Our patient carries a Likely Pathogenic Variant in TBX4 and a Variant
of Unknown Significance in SMAD1. This gene was identified in PAH patients by Nasim et al.
in 2011 [39]. The variant observed is a rare variant, found at extremely low frequency in con-
trol population databases. The role of this SAMD1 variant in the development of PAH in this
patient remains unclear. The TBX4 variant observed in our patient (c.1018C>T: p.(Arg340�))
was previously reported by Galambos et al [8]. In this study, two siblings carried this variant
and also presented transient Patent Ductus Arteriosus and Patent Foramen Ovale, and Inter-
stitial Lung Disease (ILD). During follow-up, one infant had severe ILD with mild PH and the
other one ILD without PH.
These findings are interesting due to a remarkable intra- and inter-familial variable expres-
sivity. This reflects the role of other genetic or epigenetic factors. The presence of left-to-right
shunt causes an overflow in pulmonary circulation that can lead to PH. However, this does not
fully explain these complex cases. Further investigation is needed to address the role of TBX4
in CHD and ILD.
In our study, we have also detected two de novo deletions of one copy of TBX4 in two unre-
lated individuals with a pediatric form of PAH. Strikingly, these two deletions exactly the same
size (2.2Mb) and encompass 17 genes and potential genes: CA4, LOC645638, HEATR6,
LOC653653, SCARNA20, USP32, C17orf64, APPBP2, PPM1D, TBX2, BCAS3, C17orf82,
TBX4, NACA2, BRIP1, INTS2 and MED13, suggesting a hotspot region susceptible for rear-
rangements. Comparing these variants with previously CNVs reported, we observe that many
of them have a similar size and involve the same region of chromosome (Fig 18) [7–9,13].
However, in some cases, CNV are larger and involve other genes. These findings might explain
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different phenotypes observed in these patients, and support the idea of a hot spot region due
to a flanking LCR region. 17q23 deletions have previously been associated with lung develop-
mental disorders and neonatal/pediatric PAH [13]. One of our pediatric patients (patient 8)
showed features compatible with ILD in imaging studies, needing oxygen in her first year of
life, with subsequent improvement. Furthermore, patient 7’s mother had previously had two
spontaneous abortions, one of which had pulmonary hypoplasia. We speculate that the fetus
also carried this CNV inherited from a parent. These findings are in line with a previous study
by Karolak et al. In their studies, CNV deletions do not co-segregate with lung disorders. A
loss-of-function variant per se cannot predict a possible phenotype and additional genetic
modifiers were required to cause severe lung disease. They provide evidence of the complex
compound inheritance of lung maldevelopment consisting of rare coding variants in TBX4 or
FGF10 and rare or common non-coding SNVs. Further investigation is necessary to address
the role of genetic and non-genetic modifiers in the phenotype of TBX4 variants.
5. Conclusions
PAH associated with TBX4 variants shows a wide spectrum of clinical presentations. A
severely reduced DLCO is a common finding. Genetic testing is an extremely useful tool for
cases with overlapping clinical features, and might even rule out other forms of PH such as
PVOD or PAH associated with HHT. In this respect, a PAH-specific gene diagnostic panel is a
cost and time-efficient technique to reach an accurate diagnosis.
Fig 18. Comparison of different copy number variants reported.
https://doi.org/10.1371/journal.pone.0232216.g018
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